Exhibit 99.1
     
COMPANY CONTACT:
  INVESTOR CONTACTS:
Mark Fischer-Colbrie
  Jody Cain (jcain@lhai.com)
Chief Financial Officer
  Bruce Voss (bvoss@lhai.com)
Adeza Biomedical Corporation
  Lippert/Heilshorn & Associates, Inc.
(408) 745-0975 ext 520
  (310) 691-7100
ir@adeza.com
   
For Immediate Release
ADEZA ANNOUNCES 2005 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS
Achieves 14th Consecutive Quarter of Profitability on Record Product Sales
Conference Call Begins at 4:30 p.m. Eastern Time Today
SUNNYVALE, Calif. (March 2, 2006)
– Adeza (NASDAQ: ADZA) today announced financial results for the fourth quarter and year ended December 31, 2005.
For the fourth quarter of 2005 Adeza reported record quarterly product sales of $11.9 million, an increase of 30% from product sales of $9.2 million for the fourth quarter of 2004. This increase is primarily attributable to higher sales volume of FullTerm™, The Fetal Fibronectin Test.
Adeza announced its 14th consecutive profitable quarter with income before income taxes of $2.1 million, compared with income before income taxes of $1.7 million in the 2004 fourth quarter. Net income for the fourth quarter of 2005 was $6.9 million, compared with net income of $1.6 million for the fourth quarter of 2004. The company reported a one-time benefit from income taxes of $4.8 million in the fourth quarter of 2005 primarily related to a positive impact from recording a tax asset.
Diluted earnings per share for the fourth quarter of 2005 was $0.38 based on 18.1 million shares outstanding, which includes the one-time income tax benefit of $0.27 per diluted share. This compares with diluted earnings per share of $0.11 based on 14.5 million shares outstanding for the fourth quarter of 2004. The increase in share count is primarily the result of the company’s initial public offering of 4.3 million common shares in December 2004.
Selling and marketing expenses for the 2005 fourth quarter were $5.7 million, up from $4.3 million for the comparable quarter in 2004, reflecting expansion of the company’s direct sales force and marketing programs. General and administrative expenses for the quarter increased to $2.1 million from $1.4 million in the comparable quarter of the prior year, due primarily to costs associated with operating as a public company. Research and development expenses were $1.4 million for the fourth quarter of 2005, compared with $0.7 million in the comparable quarter of the prior year, with the increase largely due to costs related to expanded product development efforts.
For the year ended December 31, 2005, product sales totaled $43.6 million, an increase of 30% from product sales of $33.6 million for the year ended December 31, 2004. Adeza reported 2005 net income of $12.3 million, or $0.69 per diluted share based on 17.9 million shares outstanding, which includes a one-time benefit from income taxes of $4.5 million, or $0.25 per diluted share. This compares with 2004 net income of $8.9 million, or $0.65 per diluted share based on 13.6 million shares outstanding, which included a one-time decrease in royalty expenses of $2.7 million.
As of December 31, 2005, Adeza had cash and cash equivalents of $89.7 million, an increase of $9.6 million compared with December 31, 2004. The increase was due primarily to income from operations. Stockholders’ equity as of December 31, 2005 was $97.4 million. Working capital as of December 31, 2005 was $96.7 million.

 


The following information was filed by Adeza Biomedical Corp on Thursday, March 2, 2006 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Adeza Biomedical Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Adeza Biomedical Corp.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account